Company & Sponsor Intelligence
Central Institute of Mental Health, Mannheim
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting0
Completed3
Countries1
Therapeutic footprint
anxietyother_neurologyother_psychiatry
Indexed studies
NCT01133301Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder
other_psychiatry · GermanyPHASE2
other_psychiatry · GermanyPHASE2
NCT00124839Naltrexone in Borderline Personality Disorder
other_psychiatry · GermanyPHASE3
other_psychiatry · GermanyPHASE3
NCT03666039Reversing Maladaptive Reorganization in Frail Brains
other_neurology · GermanyNA
other_neurology · GermanyNA
NCT00434759Social Phobia Intervention Study of Mannheim
anxiety · GermanyNA
anxiety · GermanyNA
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →